These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Stem cell transplantation for pediatric lymphoma: past, present and future. Bradley MB; Cairo MS Bone Marrow Transplant; 2008 Jan; 41(2):149-58. PubMed ID: 18084337 [TBL] [Abstract][Full Text] [Related]
4. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
5. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. Claviez A; Sureda A; Schmitz N Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738 [TBL] [Abstract][Full Text] [Related]
6. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290 [TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related]
8. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Laport GF; Williams SF Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600 [TBL] [Abstract][Full Text] [Related]
17. Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back. Verholen F; Terrettaz M; Roosnek E; Passweg JR; Chalandon Y Eur J Haematol; 2009 Sep; 83(3):273-5. PubMed ID: 19500136 [No Abstract] [Full Text] [Related]
18. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Ballova V; Ladicka M; Vranovsky A; Lakota J Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754 [TBL] [Abstract][Full Text] [Related]
19. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Morschhauser F; Brice P; Fermé C; Diviné M; Salles G; Bouabdallah R; Sebban C; Voillat L; Casasnovas O; Stamatoullas A; Bouabdallah K; André M; Jais JP; Cazals-Hatem D; Gisselbrecht C; J Clin Oncol; 2008 Dec; 26(36):5980-7. PubMed ID: 19018090 [TBL] [Abstract][Full Text] [Related]
20. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Tey S; Butler J; Durrant S; Hill G; Morton J; Kennedy G Bone Marrow Transplant; 2005 Sep; 36(6):553-4; author reply 554. PubMed ID: 16044146 [No Abstract] [Full Text] [Related] [Next] [New Search]